BioNTech SE

Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in 2008 by scientists and physicians to translate science into survival by combining fundamental research and operational excellence. At BioNTech, we have been conducting fundamental research of mRNA technologies in the field of individualized cancer medicine for more than a decade. Some of our colleagues, including our co-founders, have been researching and developing mRNA-based vaccines for more than 25 years. Ready to join us on this journey? Explore the opportunities and become part of a team that aspires to turn bold ideas into real-world solutions: www.biontech.com/careers 🔗 Privacy Statement: https://www.biontech.com/int/en/home/data-privacy-statement.html 🔗 Imprint: https://www.biontech.com/int/en/home/imprint.html

Miltenyi Biotec

For over 30 years, Miltenyi Biotec has been a major provider of products and services that drive biomedical research and boost cell and gene therapy. More than 4,700 employees in 23 countries combine excellence in research with innovative products to create cutting-edge solutions that make cancer and other disease history. Our expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. At Miltenyi Biotec, scientists, engineers, software developers and many other professionals work together to improve human health by providing smarter cellular technology solutions to researchers and clinicians worldwide.

Eppendorf

Eppendorf is a leading life science company that develops and sells instruments, consumables, and services for liquid-, sample-, and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers, and DNA amplification equipment as well as ultra-low temperature freezers, fermentors, bioreactors, CO2 incubators, shakers, and cell manipulation systems. Consumables such as pipette tips, test tubes, microtiter plates, and disposable bioreactors complement the range of highest-quality premium products. Eppendorf products are most broadly used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the chemical and food industries. They are also aimed at clinical and environmental analysis laboratories, forensics, and industrial laboratories performing process analysis, production, and quality assurance. Eppendorf was founded in Hamburg, Germany in 1945 and has about 5000 employees worldwide. The company has subsidiaries in 33 countries and is represented in all other markets by distributors. Imprint: www.eppendorf.com/imprint

Bruker BioSpin

Bruker is a leading global manufacturer of analytical measurement systems for the life and material sciences. For more than 60 years, our high-performance scientific instruments as well as analytical and diagnostic solutions have enabled the study of living organisms and substances. Bruker BioSpin Group develops, manufactures, and markets instruments based on magnetic resonance technology, such as nuclear magnetic resonance (NMR), electron paramagnetic resonance (EPR) spectrometers, and preclinical imaging systems. Through these world-class technologies, Bruker BioSpin is helping science and development find answers to key questions facing our society, thereby improving lives in a sustainable way. Whether in operations, R&D, sales, or administration, our employees are at the heart of developing and manufacturing as well as selling and operating our cutting-edge and innovative technologies. Privacy Policy: https://goto.bruker.com/LI-BioSpin-PrivacyPolicy Imprint: • Bruker BioSpin GmbH & Co. KG • Rudolf-Plank-Straße 23, 76275 Ettlingen, Germany • Limited Partnership with Limited Company as General Partner • Patrick Minhorst, Dr. Wulf-Ingo Jung, Bernd Gleixner • [email protected] • Mannheim HRA 711508 • Markus Ziegler (Editorial Content) • VAT #DE 362916828 Contacts: - Phone: +1 978-663-3660 - Fax: +1 978-663-5585 - Email: [email protected]

CureVac

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. Further information can be found at www.curevac.com.